Supporting Shared Decision-making About Surveillance After Breast Cancer With Personalized Recurrence Risk Calculations: Development of a Patient Decision Aid Using the International Patient Decision AIDS Standards Development Process in Combination With a Mixed Methods Design.
Jet Wies Ankersmid, Sabine Siesling, Luc J A Strobbe, Johanna M Meulepas, Yvonne E A van Riet, Noel Engels, Janine C M Prick, Regina The, Asako Takahashi, Mirjam Velting, Cornelia F van Uden-Kraan, Constance H C Drossaert
Author Information
Jet Wies Ankersmid: Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands. ORCID
Sabine Siesling: Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands. ORCID
Luc J A Strobbe: Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, Netherlands. ORCID
Johanna M Meulepas: Department of Quality and Safety, Catharina Hospital, Eindhoven, Netherlands. ORCID
Yvonne E A van Riet: Department of Surgery, Catharina Hospital, Eindhoven, Netherlands. ORCID
BACKGROUND: Although the treatment for breast cancer is highly personalized, posttreatment surveillance remains one-size-fits-all: annual imaging and physical examination for at least five years after treatment. The INFLUENCE nomogram is a prognostic model for estimating the 5-year risk for locoregional recurrences and second primary tumors after breast cancer. The use of personalized outcome data (such as risks for recurrences) can enrich the process of shared decision-making (SDM) for personalized surveillance after breast cancer. OBJECTIVE: This study aimed to develop a patient decision aid (PtDA), integrating personalized risk calculations on risks for recurrences, to support SDM for personalized surveillance after curative treatment for invasive breast cancer. METHODS: For the development of the PtDA, the International Patient Decision Aids Standards development process was combined with a mixed methods design inspired by the development process of previously developed PtDAs. In the development, 8 steps were distinguished: establishing a multidisciplinary steering group; definition of the end users, scope, and purpose of the PtDA; assessment of the decisional needs of end users; defining requirements for the PtDA; determining the format and implementation strategy for the PtDA; prototyping; alpha testing; and beta testing. The composed steering group convened during regular working-group sessions throughout the development process. RESULTS: The "Breast Cancer Surveillance Decision Aid" consists of 3 components that support the SDM process: a handout sheet on which personalized risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualized and which contains an explanation about the decision for surveillance and a login code for a web-based deliberation tool; a web-based deliberation tool, including a patient-reported outcome measure on fear of cancer recurrence; and a summary sheet summarizing patient preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Beta testing is currently ongoing. CONCLUSIONS: We developed an acceptable and usable PtDA that integrates personalized risk calculations for the risk for recurrences to support SDM for surveillance after breast cancer. The implementation and effects of the use of the "Breast Cancer Surveillance Decision Aid" are being investigated in a clinical trial.
